SEC Comment Letter for KAZIA THERAPEUTICS (KZIA) — Mar 25, 2026
KAZIA THERAPEUTICS LTD
Date: March 25, 2026 · CIK: 0001075880 · Accession: 0000000000-26-003011
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-294392
Letter
Re: Kazia Therapeutics Limited Registration Statement on Form F-3 Filed March 18, 2026 File No. 333-294392 Dear John Friend:
March 25, 2026
John Friend Chief Executive Officer Kazia Therapeutics Limited Three International Towers Level 24, 300 Barangaroo Avenue Sydney, NSW, 2000, Australia
This is to advise you that we have not reviewed and will not review your registration statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Jessica Dickerson at 202-551-8013 with any questions.
Sincerely,
Division of
Corporation Finance
Office of Life
Sciences
cc: Sebastian A. Bacon, Esq.
Show Raw Text
<DOCUMENT> <TYPE>TEXT-EXTRACT <SEQUENCE>2 <FILENAME>filename2.txt <TEXT> March 25, 2026 John Friend Chief Executive Officer Kazia Therapeutics Limited Three International Towers Level 24, 300 Barangaroo Avenue Sydney, NSW, 2000, Australia Re: Kazia Therapeutics Limited Registration Statement on Form F-3 Filed March 18, 2026 File No. 333-294392 Dear John Friend: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Jessica Dickerson at 202-551-8013 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Sebastian A. Bacon, Esq. </TEXT> </DOCUMENT>